Polypid Ltd (PYPD)

$3.30 +0.11 (3.45%)
Market Cap 15.30M
Revenue (ttm) 0.00
Net Income (ttm) -23.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 3.57
Volume 27,400
Avg Vol 32,278
Day's Range N/A - N/A
Shares Out 4.80M
Stochastic %K 90%
Beta 1.32
Analysts Strong Sell
Price Target $10.33

Latest News on PYPD

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

Dec 26, 2024, 10:31 AM EST - 22 days ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA AVXL

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 23, 2024, 7:22 PM EST - 25 days ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Dec 11, 2024, 7:00 AM EST - 5 weeks ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 29, 2024, 1:05 PM EST - 7 weeks ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 2:06 PM EST - 2 months ago

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Nov 7, 2024, 7:00 AM EST - 2 months ago

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Oct 30, 2024, 8:00 AM EDT - 2 months ago

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Oct 21, 2024, 7:00 AM EDT - 3 months ago

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Oct 1, 2024, 7:00 AM EDT - 3 months ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid to Participate in Three Upcoming Fall Investor Conferences

Sep 3, 2024, 7:00 AM EDT - 4 months ago

PolyPid to Participate in Three Upcoming Fall Investor Conferences

PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 1:25 PM EDT - 5 months ago

PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

Aug 1, 2024, 8:31 PM EDT - 6 months ago

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

Jul 31, 2024, 7:00 AM EDT - 6 months ago

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

Jun 10, 2024, 7:00 AM EDT - 7 months ago

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript

May 9, 2024, 10:38 PM EDT - 9 months ago

PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 8, 2024, 7:00 AM EDT - 9 months ago

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

PolyPid to Participate in Citizens JMP Life Sciences Conference

May 1, 2024, 7:00 AM EDT - 9 months ago

PolyPid to Participate in Citizens JMP Life Sciences Conference

PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Apr 30, 2024, 7:00 AM EDT - 9 months ago

PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024

Apr 24, 2024, 7:00 AM EDT - 9 months ago

PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

Feb 28, 2024, 7:00 AM EST - 11 months ago

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript

Feb 14, 2024, 11:13 AM EST - 1 year ago

PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 14, 2024, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial

Feb 12, 2024, 7:00 AM EST - 1 year ago

PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial

PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

Jan 31, 2024, 7:00 AM EST - 1 year ago

PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

PolyPid Announces Private Placement for $16 Million in Gross Proceeds

Jan 4, 2024, 4:32 PM EST - 1 year ago

PolyPid Announces Private Placement for $16 Million in Gross Proceeds

PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript

Nov 12, 2023, 1:08 AM EST - 1 year ago

PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 8, 2023, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results

PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

Nov 7, 2023, 7:00 AM EST - 1 year ago

PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023

Nov 1, 2023, 7:00 AM EDT - 1 year ago

PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023

PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Oct 11, 2023, 7:00 AM EDT - 1 year ago

PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023

Oct 9, 2023, 7:00 AM EDT - 1 year ago

PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023

PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform

Oct 4, 2023, 7:00 AM EDT - 1 year ago

PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform

PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 22, 2023, 7:00 AM EDT - 1 year ago

PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health

Sep 21, 2023, 7:34 AM EDT - 1 year ago

PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health

PolyPid Announces Reverse Share Split

Sep 20, 2023, 9:15 AM EDT - 1 year ago

PolyPid Announces Reverse Share Split

PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀

Sep 19, 2023, 7:00 AM EDT - 1 year ago

PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀

PolyPid Ltd (PYPD) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 12:55 PM EDT - 1 year ago

PolyPid Ltd (PYPD) Q2 2023 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Aug 9, 2023, 7:00 AM EDT - 1 year ago

PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results

PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023

Jul 26, 2023, 7:00 AM EDT - 1 year ago

PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023

PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections

Jun 29, 2023, 8:00 AM EDT - 1 year ago

PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections

PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

Jun 22, 2023, 7:00 AM EDT - 1 year ago

PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market

Jun 5, 2023, 4:02 PM EDT - 1 year ago

PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market

PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

May 22, 2023, 9:00 AM EDT - 1 year ago

PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Ltd. (PYPD) Q1 2023 Earnings Call Transcript

May 10, 2023, 12:50 PM EDT - 1 year ago

PolyPid Ltd. (PYPD) Q1 2023 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 10, 2023, 7:00 AM EDT - 1 year ago

PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results

PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023

Apr 26, 2023, 7:00 AM EDT - 1 year ago

PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023

PolyPid to Participate in Upcoming Investor Conferences

Apr 24, 2023, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Upcoming Investor Conferences

PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds

Mar 31, 2023, 12:00 PM EDT - 1 year ago

PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds

PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants

Mar 29, 2023, 7:59 AM EDT - 1 year ago

PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants

PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares

Mar 28, 2023, 4:05 PM EDT - 1 year ago

PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares